Drug Profile
Retinal disorders therapeutics - Sylentis
Alternative Names: SLY 136001; SYL 136001v10Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Sylentis
- Class Eye disorder therapies; Gene therapies; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Retinal disorders
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for preclinical development in Retinal-disorders in Spain (Ophthalmic, Drops)
- 12 Jul 2016 Preclinical trials in Retinal disorders in Spain (unspecified route)